For example, the overexpression of PLOD2 and LOX has been correlated with poor outcomes in multiple cancers, and their detection in prostate tumors may help stratify patients who would benefit from more aggressive treatments or ECM-targeting therapies. The gene discussed is LOX; the disease is prostate neoplasm.